Nonetheless, localized delivery is feasible only for accessible or early-stage tumors and is impractical for metastatic or deeply seated cancers—particularly those such as gliomas or disseminated gastrointestinal tumors, where KIF4A is highly oncogenic. The gene discussed is KIF4A; the disease is glioma.